Glycocholic Acid: A Comprehensive Reference
1. Identity and Chemical Characterization
1.1 Names and Nomenclature
Glycocholic acid is chemically designated as N-(3α,7α,12α-Trihydroxy-5β-cholan-24-oyl)-glycine. It is also known by the synonyms cholylglycine, glycocholate (the anionic form), and N-choloylglycine. Glycocholic acid is a crystalline bile acid involved in the emulsification of fats; it occurs as a sodium salt in the bile of mammals, is a conjugate of cholic acid with glycine, and its anion is called glycocholate.
1.2 Molecular Properties
The molecular formula is C26H43NO6, with a molecular weight of 465.62. This compound exhibits weak acidity and appears as a white crystalline powder with a bitter taste. The CAS Registry Number is 475-31-0. Bile salts such as glycocholic acid contain a steroid core structure composed of four fused rings, including three cyclohexane rings (the A, B, and C rings) and one cyclopentane ring (the D ring), with the steroid core remaining unchanged across all bile salts despite variation in hydroxyl group number and orientation.
Glycocholic acid is classified by ChEBI as a bile acid glycine conjugate having cholic acid as the bile acid component. Bile acids, including glycocholic acid, are steroidal amphipathic molecules. This amphiphilicity — the possession of both hydrophilic and hydrophobic regions within the same molecule — is the structural basis for its detergent-like behavior and its role in fat emulsification.
1.3 Natural Sources
Glycocholic acid is biosynthesized from cholesterol in the liver and conjugated with glycine, playing a crucial role in the regulation of metabolism and digestion. The primary bile acids are synthesized in the liver cells from cholesterol and are excreted into the bile as such. The biosynthesis of two primary bile acids — chenodeoxycholic and cholic acids — begins in the liver cells by cytochrome P450 oxidation of cholesterol. When these two bile acids are secreted into the intestinal lumen, intestinal microflora dehydroxylates a portion of each to form the secondary bile acids. Prior to secreting any of the four bile acids, the liver cells may conjugate them with one of two amino acids: glycine or taurine.
In the liver, cholic acid is chemically linked to one of two amino acids (taurine or glycine) to form the conjugated cholic acids (i.e., L-glycocholate and taurocholate). These conjugated cholic acids are then stored in the gallbladder until food consumption. The major bile salts of humans found predominantly in the bile include cholic acid derivatives — taurocholic acid and glycocholic acid — and chenodeoxycholic acid (CDCA) derivatives.
Glycocholic acid is present in the bile of a wide range of mammals. Different animal biles can be explicitly distinguished by their major characteristic bile acids: glycocholic acid, cholic acid, and taurocholic acid are characteristic of cattle bile, while tauroursodeoxycholic acid and taurochenodeoxycholic acid characterize bear bile, glycohyodeoxycholic acid and glycochenodeoxycholic acid characterize pig bile, and taurocholic acid characterizes snake bile. In pig bile preparations (PBP), a study using ¹H-NMR and LC-MS showed that glycocholic acid (GCA) was the second most abundant bile acid in PBP at 38.59 nmol/mg.
1.4 Common Forms and Preparations
Glycocholic acid is commercially available in several forms: as the free acid, as the sodium salt (sodium glycocholate), and as a pharmaceutical-grade raw material synthesized from cholic acid. These bile salts are secreted by the liver as constituents of bile, which is carried via the biliary duct system to the gallbladder. Bile is concentrated in the gallbladder for ultimate discharge into the duodenum where the bile salts are intimately associated with dietary lipids and their various digestive products. Due to its amphiphilic molecular structure, glycocholic acid is primarily used as a pharmaceutical excipient. Glycocholic acid can improve the oral bioavailability of drugs with low water solubility and low permeability through the formation of micelles and saponification. As a pharmaceutical excipient, glycocholic acid can form mixed micelles with phospholipids, serving as a vehicle for the injection administration of insoluble drugs.
2. Traditional and Historical Use
2.1 Traditional Chinese Medicine
Glycocholic acid has never historically been used in isolation as a discrete compound. Rather, it is one of the principal bioactive constituents of animal bile preparations that have been employed medicinally for millennia. With a history of more than 1,000 years in China, Chinese medicine is primarily derived from natural animals and plants. Bile, an essential component of animal medicines produced in the digestive fluid of the liver, has a long history of use in traditional Chinese medicine.
The Shennong Bencao Jing from the Han Dynasty records the use of carp bile to treat redness, swelling and pain in the eyes, blindness, and deafness, while Zhang Zhongjing in the Jin Yi Lun documents the functions of pig bile, such as suppressing coughs and relieving asthma symptoms, as well as its anti-inflammatory and anti-bacterial properties. Li Shizhen included more than 30 kinds of bile acid-containing herbs — such as bull bile, sheep bile, bear bile, and pig bile — in his Bencao Gangmu, all of which are listed in the Dictionary of Chinese Medicine because of their strong medicinal effects, significant curative effects, and abundant resources, making them widely used in pill powder or other traditional Chinese medicine or Western medicine preparations.
In the Chinese Tang Materia Medica, the worldwide first state pharmacopoeia collected during the classical period of the T'ang dynasty (618–907 CE), it was stated that "bear bile which tastes bitter can be used to treat jaundice, … intractable diarrhea in summer and cardialgia." In Eastern Asian societies, the belief in a therapeutic effect of bile constituents has persisted for millennia.
Animal biles and gallstones, which contain high amounts of bile acids including glycocholic acid, have been used as traditional medicines for a long history in many countries including China, Japan, Korea, and India. Different species of biles are recorded in national pharmacopoeias.
In some regions, people also use bile in specific food therapy or culinary practices, such as cattle bile powder, which is a dried product of bile appearing as green-brown or brownish chunks or powder. Bile acids and bile salts are the primary bioactive components of animal bile that exert therapeutic effects.
Analytically, glycocholic acid has been confirmed as a key marker molecule in authenticity testing of traditional bile-based preparations. Researchers have established a method to identify natural bezoar, artificial bezoar, and in vitro cultured bezoar, finding that glycocholic acid, glycodeoxycholic acid, and taurocholic acid were detected in both natural and artificial bezoar, though the content of taurocholic acid differed, successfully distinguishing between the various types of bezoar medicinal materials.
It is important to note that in traditional contexts, bile-containing preparations were administered as complex multicomponent mixtures; the attribution of specific effects to glycocholic acid as an isolated constituent is a product of modern analytical and pharmacological science.
3. Key Constituents, Biochemistry, and Mechanisms of Action
3.1 Structural Basis for Biological Activity
Glycocholic acid is a glycine-conjugated form of the primary bile acid cholic acid and has roles in the emulsification of fats. Bile acids including glycocholic acid are amphipathic molecules that facilitate the uptake of lipids, and their levels fluctuate in the intestine as well as in the blood circulation depending on food intake. Besides their role in dietary lipid absorption, bile acids function as signaling molecules capable of activating specific receptors.
3.2 Enterohepatic Circulation
Bile acids are physiological detergent molecules and are highly cytotoxic. They undergo enterohepatic circulation and play important roles in generating bile flow and facilitating biliary secretion of endogenous metabolites and xenobiotics and intestinal absorption of dietary fats and lipid-soluble vitamins. Bile acid synthesis, transport, and pool size are therefore tightly regulated under physiological conditions. Conjugated bile acids are absorbed passively from all sites of the gastrointestinal tract, pass through the duodenum–jejunum, and are largely absorbed in the ileum by an active transport mechanism. Bile acids are deconjugated by bacteria in the intestine and are recycled back to the liver for reconjugation (secondary bile acids).
3.3 Receptor-Mediated Signaling: FXR and TGR5
Bile acids including glycocholic acid bind and activate both TGR5 and other nuclear receptors, among which is FXR (Farnesoid X Receptor). These two receptors are the principal mediators of bile acid signaling in metabolism and inflammation.
FXR (Farnesoid X Receptor): In addition to their role in the formation of intestinal micelles, bile acids serve as signaling molecules through two major receptors, FXR and TGR5. FXR is a nuclear receptor activated by bile acids such as chenodeoxycholic acid. FXR is predominantly expressed in the liver, kidneys, and intestine, and controls lipid and carbohydrate homeostasis. Activation of FXR reduces the synthesis of liver lipoproteins, as well as the levels of plasma triglycerides and cholesterol. Glycocholic acid reduces expression of the gene encoding the farnesoid X receptor (FXR) and increases expression of the genes encoding the bile acid receptors TGR5 and S1PR2 in SNU-245 cells when used at a concentration of 1.6 μmol/ml.
TGR5 (Takeda G protein-coupled Receptor 5 / GPBAR1): TGR5 (also designated as GPBAR1 or M-BAR) is a G-protein coupled bile acid receptor highly expressed in the intestine and gallbladder. TGR5 is activated by both primary and secondary bile acids, but demonstrates the highest affinity for lithocholic acid. TGR5 mediates several biological effects of bile acids including a hypermetabolic effect, stimulation of gallbladder filling, and improved insulin sensitivity. TGR5, a membrane-bound bile acid receptor, is well-known for its roles in regulation of energy homeostasis and glucose metabolism, and mice lacking TGR5 were much more susceptible to LPS-induced acute gastric inflammation than wild-type mice, suggesting TGR5 is a negative regulator of gastric inflammation through antagonizing the NF-κB signaling pathway.
Feedback inhibition of bile acid synthesis: Hepatic bile acid depletion increased HMG-CoA reductase activity fourfold and cholesterol 7α-hydroxylase activity threefold, which were reduced 48% and 51% respectively from their maximum levels during replacement with glycocholic acid, demonstrating that glycocholic acid participates in the feedback regulation of both cholesterol and bile acid biosynthesis.
3.4 Fat Digestion and Vitamin Absorption
Glycocholic acid plays a crucial role in enhancing lipase activity, catalyzing fat breakdown, and promoting bile secretion. Bile acids act in bile to solubilize cholesterol (which is totally insoluble in water) with phospholipids in mixed micelles. Once secreted into the intestine, bile acids help to emulsify fats and aid in their digestion. Bile acids including glycocholic acid play an important role in lipid absorption and cholesterol catabolism, and may be promising therapeutic agents to increase intestinal absorption of vitamins, to correct biliary cholesterol saturation, and to treat cholesterol gallstones and cholestatic liver diseases.
3.5 Anti-Inflammatory, Antioxidant, and Other Pharmacological Properties
Recent studies have revealed additional therapeutic properties of glycocholic acid including anti-inflammatory, antipyretic, antioxidant, and antibacterial effects. It is inferred that glycocholic acid may play a role in regulating glucose and lipid metabolism and inhibiting the expression of gluconeogenesis-related genes. These pharmacological properties have been characterized primarily in preclinical and in vitro settings; the mechanisms underlying these activities are still under active investigation.
3.6 Drug Delivery Enhancement
Glycocholic acid (250 μM) increases the intracellular accumulation and cytotoxicity of epirubicin in Caco-2 cells, as well as decreases expression of the genes encoding multidrug resistance protein 1 (MDR1), MDR-associated protein 1 (MRP1), and MRP2 when used alone or in combination with epirubicin. This property has led to exploration of glycocholic acid as a pharmaceutical excipient to enhance oral bioavailability of poorly absorbed drugs.
4. Scientific Evidence by Area of Use
4.1 Liver Disease: Serum Biomarker and Diagnostic Use
The most extensively characterized clinical application of glycocholic acid measurement is as a serum biomarker of liver function. Under normal physiological conditions, the liver absorbs glycocholic acid from the bloodstream, where its concentration remains low. However, when liver cells are damaged or impaired in their ability to excrete bile acids, peripheral blood levels of glycocholic acid are elevated. Consequently, glycocholic acid may serve as an early diagnostic indicator of abnormalities related to liver and bile function.
Chronic Active Hepatitis (clinical evidence, weak–moderate): In a published observational study, serum levels of fasting glycocholic acid were measured in various non-cirrhotic liver diseases. Forty-five patients were evaluated — 15 with chronic active hepatitis and 30 with mild liver diseases including chronic persistent hepatitis, steatosis, and minimal changes. Increased levels of glycocholic acid were found in 53.3% of chronic active hepatitis cases and in 10% of mild liver disease cases (P = 0.003), and the levels reached by patients with chronic active hepatitis were higher than those in patients with mild liver disease. The specificity of glycocholic acid was high in the detection of chronic active hepatitis patients at different cut-off levels, and glycocholic acid appeared to reflect histological severity in this group of non-cirrhotic liver diseases. This was a single-centre, relatively small study and the findings are exploratory in nature.
Alcohol-Associated Hepatitis (clinical evidence, observational): Compared with control patients and patients with alcohol use disorder, patients with alcohol-associated hepatitis show a significant increase of both total and conjugated bile acids in the serum, positively correlated with disease severity. Bile acid composition analysis shows significantly elevated levels of glycocholic acid, taurocholic acid, and taurochenodeoxycholic acid in patients with alcohol-associated hepatitis.
Clinical monitoring: In clinical practice, radioimmunoassay (RIA) is widely used to analyze the levels of glycocholic acid in serum, which is of great significance for assessing the severity of liver disease, monitoring disease progression, and predicting prognosis.
4.2 Congenital Bile Acid Synthesis Disorders
Congenital bile acid synthesis disorders are caused by enzyme deficiencies during the synthesis process and typically manifest in newborns or infants, though they can also present in adulthood. Symptoms include cholestasis, fat-soluble vitamin deficiencies, coagulopathy, chronic liver disease, growth retardation, or neurological impairment.
Studies have shown that glycocholic acid can treat bile acid synthesis disorders due to bile acid-CoA:amino acid N-acyltransferase (BAAT) deficiency. In 2012, the Cincinnati Children's Hospital Medical Center in the United States advanced to Phase III clinical trials for the use of glycocholic acid in treating patients with congenital bile acid synthesis disorders. Over a span of 10 years, they selected male and female patients aged between 1 week and 85 years. The primary measurement was the change in atypical bile acid synthesis in urine, analyzed by mass spectrometry, while secondary measurements included liver function. The evidence for glycocholic acid in BAAT deficiency is thus derived from clinical trials and peer-reviewed literature, though the patient populations involved are rare, making large randomized controlled trial data extremely difficult to obtain.
4.3 Intrahepatic Cholestasis of Pregnancy (ICP)
Glycocholic acid has attracted considerable research attention as a biomarker in intrahepatic cholestasis of pregnancy. Intrahepatic cholestasis of pregnancy (ICP) is a common and severe disease that occurs in the third trimester of pregnancy, with an incidence ranging from 0.1–2%. The condition is always accompanied by pruritus, elevated hepatic liver enzymes, and elevated serum total bile acid (TBA) levels.
Clinical studies have confirmed that the risk of fetal adverse complications is closely related to maternal glycocholic acid levels, with their incidence increasing significantly with the increase in maternal glycocholic acid levels. Women with ICP were found to have significantly elevated levels of both serum and placental glycocholic acid as compared to healthy controls.
A metabolomics-based study (40 ICP patients and 40 healthy pregnant controls) found that in integrated proteomic and metabolomic analysis of placental tissue, ACOX1, L-palmitoylcarnitine, and glycocholic acid were identified as three potential biomarkers. Expression levels of both placental and serum ACOX1, L-palmitoylcarnitine, and glycocholic acid were significantly higher in third-trimester ICP patients, with areas under the ROC curves of 0.823, 0.896, and 0.985 respectively. Expression levels were also significantly higher in first- and second-trimester ICP patients, with areas under the ROC curves of 0.726, 0.657, and 0.686 in the first trimester. Together, levels of the three biomarkers increased the diagnostic value (AUC: 0.993 for the third, 0.891 for the second, and 0.932 for the first trimesters).
A further study of 95 ICP patients found that the percentage of conjugated bile acids increased in ICP patients; specifically, taurocholic acid accumulated in late-onset ICP patients, and glycocholic acid predominated in early-onset ICP patients. A model was established to provide GCA and TCA as preterm birth predictive biomarkers, and changes in GCA and TCA may be helpful for evaluating UDCA treatment efficacy.
The evidence for glycocholic acid as a diagnostic and prognostic biomarker in ICP is clinically meaningful and consistent across multiple observational studies, though it is based on case-control and cohort designs rather than interventional trials. Glycocholic acid is measured as a serum marker, not administered as a treatment in this context.
4.4 Liver Fibrosis and Cholestasis: Pathological Role
Research has identified a potential pathological contribution of elevated glycocholic acid to liver fibrosis in the setting of cholestasis. Data from an in vitro and cellular study showed that GCA can induce the expression of connective tissue growth factor (CTGF) in hepatocytes by promoting the nuclear translocation of yes-associated protein (YAP), thereby activating hepatic stellate cells. These findings help to elucidate the contribution of GCA to the progression of hepatic fibrosis in cholestatic disease. Disorders arising from defects in enterohepatic circulation are generally referred to as cholestatic diseases or cholestasis, defined as the impairment of bile acid flow resulting in a toxic accumulation of bile acids and their metabolites in the liver and systemic circulation. Such impairments may be driven by genetic, hormonal, hepatobiliary, metabolic, exogenous, autoimmune or alloimmune factors, and can lead to inflammation, fibrosis, cirrhosis, hepatocyte dysfunction, hepatocellular carcinoma, cholangiocarcinoma, and ultimately end-stage liver disease.
The bile acid components of bile-based TCMs have dual "Yin and Yang" effects in the treatment of liver diseases — showing therapeutic actions such as anti-inflammation, hepatoprotection, and anti-fibrosis, while also potentially promoting disease through certain constituents like TCA and GCA. This dual nature creates a complex balance between benefit and risk. Evidence for glycocholic acid's fibrogenic role at elevated concentrations is currently at the preclinical and cellular level; there are no clinical trials directly testing this mechanism in humans.
4.5 Cholangiocarcinoma
The bile acid composition ratio of glycocholic acid is elevated in bile of patients with cholangiocarcinoma compared with patients with pancreatic cancer or benign biliary diseases. This observation is based on comparative compositional analyses in patient cohorts and is considered hypothesis-generating. Glycocholic acid has not been tested as a treatment for cholangiocarcinoma; rather, its altered ratio is studied as a potential diagnostic or disease-stratification marker.
4.6 Colorectal Cancer Risk: Epidemiological Association
Several prospective and epidemiological studies have examined the relationship between circulating bile acid profiles — including glycocholic acid — and colorectal cancer (CRC) risk. In a prospective study, positive associations were observed between prediagnostic plasma levels of seven conjugated bile acid metabolites, including glycocholic acid, and colon cancer risk. These findings support experimental data suggesting that high circulating bile acids promote colon cancer risk.
The plasma levels of seven conjugated bile acid metabolites, including glycocholic acid, taurine-conjugated cholic acid, glycodeoxycholic acid, taurochenodeoxycholic acid, and taurodeoxycholic acid, were positively correlated with risk of colon cancer. In a recently conducted prospective, nested case-control study, circulating bile acids were strongly and directly associated with risk for incident CRC. Furthermore, secondary bile acids, derived via metabolism by gut bacteria of primary bile acids that escape enterohepatic circulation, are promoters of oxidative stress, inflammation, and DNA damage.
The evidence linking elevated glycocholic acid to CRC risk is observational and prospective, establishing statistical associations rather than causation. The relationship is embedded in the broader biology of bile acid metabolism and gut microbiota composition, and glycocholic acid's contribution independently of other correlated bile acids has not been definitively isolated.
4.7 Drug Bioavailability Enhancement (Pharmaceutical Excipient Role)
Glycocholic acid can improve the oral bioavailability of drugs with low water solubility and low permeability through the formation of micelles and saponification. As a pharmaceutical excipient, glycocholic acid can form mixed micelles with phospholipids, serving as a vehicle for the injection administration of insoluble drugs. This characteristic gives it potential application value in drug delivery systems, especially in improving drug solubility and bioavailability. This application area is well-characterized at the formulation and in vitro level; it represents the most consistently utilized current practical use of glycocholic acid in the pharmaceutical industry.
4.8 Total Parenteral Nutrition (TPN): Clinical Safety Concern
A prospective, randomized-controlled trial examined the effects of glycocholic acid-containing vitamin preparations in a TPN setting. To evaluate the effects of total parenteral nutrition with a vitamin preparation containing high doses of glycocholic acid in patients with and without liver disease, 74 patients (36 of them with hepatobiliary disease) received total parenteral nutrition for a mean of 16 days, either with Cernevit or control vitamin supplements. Patients were closely monitored for clinical and biochemical parameters including serum bile acid profiles. Serum glycocholic acid increased in patients with liver disease treated with Cernevit, whereas total bile acids did not significantly change. Other liver function tests remained stable during treatment. This finding highlights a specific consideration for patients with pre-existing hepatobiliary disease receiving parenteral vitamin formulations that contain glycocholic acid.
5. Body Systems and Health Areas
5.1 Hepatobiliary System
Glycocholic acid is most centrally associated with the hepatobiliary system. It is synthesized in the liver, stored in the gallbladder, secreted into the bile, and is a principal component of the bile acid pool. Its serum concentration is a sensitive indicator of hepatocellular function. In cholestasis, impaired bile flow leads to accumulation of bile acids in the liver, causing hepatocyte and biliary injury and inflammation. Chronic cholestasis is associated with fibrosis, cirrhosis, and eventually liver failure.
5.2 Gastrointestinal System
In the gastrointestinal tract, glycocholic acid acts as a surfactant molecule essential for the solubilization and absorption of dietary fat, cholesterol, and fat-soluble vitamins (A, D, E, K). Intestinal bacteria convert primary bile acids into secondary bile acids, which are reabsorbed along with unchanged primary bile acids in the terminal ileum. The gut microbiota's ability to deconjugate and biotransform glycocholic acid represents a key interface between bile acid chemistry and the intestinal microbiome.
5.3 Metabolic and Endocrine System
Through its activation of FXR and TGR5, glycocholic acid participates in the regulation of lipid, glucose, and energy metabolism. Bile acid signaling is a critical regulator of glucose and energy metabolism, mainly through the nuclear receptor FXR and the G protein-coupled receptor TGR5. Activation of FXR reduces the synthesis of liver lipoproteins, as well as the levels of plasma triglycerides and cholesterol.
5.4 Reproductive System and Pregnancy
The accumulation of glycocholic acid during ICP has direct implications for fetal and maternal health. The pathophysiological basis of ICP is hypercholic acidemia. Both animal and in vitro experiments have confirmed that hypercholic acidemia is capable of inducing apoptosis of placental cells.
5.5 Immune and Inflammatory System
TGR5 is abundantly expressed in CD14-positive monocytes and macrophages, where its activation mediates immunosuppressive effects. Through this pathway, glycocholic acid and other bile acid receptor ligands may modulate innate immune responses. TGR5 activation antagonizes NF-κB signaling through suppressing its transcription activity, the phosphorylation of IκBα, and p65 translocation, suggesting that TGR5 antagonizes inflammation at least in part by inhibiting NF-κB signaling.
6. Dosage Forms and Reported Dosages
As a naturally occurring endogenous metabolite, glycocholic acid does not have a conventional "supplement dose" in the way that most dietary supplements do. The doses reported in scientific and clinical literature relate primarily to its use in treating rare metabolic disorders or to exposures in pharmaceutical formulations.
- Pharmaceutical excipient (injectable and oral formulations): Glycocholic acid at a concentration of 250 μM has been shown in laboratory models to increase the intracellular accumulation of epirubicin in Caco-2 cells and to increase absorption of epirubicin into everted sacs of rat ileum and jejunum.
- TPN vitamin preparation (clinical context): In a prospective, randomized-controlled trial, 74 patients received total parenteral nutrition for 16 ± 11 days either with Cernevit (a vitamin preparation containing glycocholic acid) or control vitamin supplements. The exact dose of glycocholic acid within the Cernevit formulation was the clinical variable of interest; this study was designed to evaluate safety in hepatobiliary disease rather than to test efficacy of glycocholic acid per se.
- Congenital bile acid synthesis disorders (Phase III trial): The Cincinnati Children's Hospital Medical Center advanced to Phase III clinical trials for the use of glycocholic acid in treating patients with congenital bile acid synthesis disorders; over a span of 10 years, they selected male and female patients aged between 1 week and 85 years, using atypical bile acid synthesis in urine as the primary measure. Specific dosages used in this trial are not reportable from the sources available in this review.
- Analytical reference concentration (FXR/TGR5 signaling studies): Glycocholic acid reduces expression of the FXR gene and increases expression of TGR5 and S1PR2 in SNU-245 cells at a concentration of 1.6 μmol/ml.
7. Safety Considerations and Known Interactions
7.1 Pathological Accumulation and Hepatotoxicity
Glycocholic acid is an endogenous molecule with well-established physiological roles, but elevated concentrations in pathological states are associated with tissue injury. Bile acids are physiological detergent molecules and are highly cytotoxic. Disorders arising from defects in enterohepatic circulation are generally referred to as cholestasis, defined as the impairment of bile acid flow resulting in a toxic accumulation of bile acids and their metabolites in the liver and systemic circulation.
A molecule called CHOP is involved in the ER stress pathway, and CHOP knockout models have shown decreased liver fibrosis. Exposure of hepatocytes to elevated bile acid concentrations as seen in obstructive cholestasis causes an increase in cytokines (IL-1β and IL-10), chemokines such as macrophage inflammatory protein, and cell adhesion molecules (ICAM-1 and VCAM-1), thereby influencing immune cell levels and function.
7.2 Pro-Fibrotic Effects at Elevated Concentrations
Research suggests that glycocholic acid induces the expression of CTGF in hepatocytes by promoting the nuclear translocation of YAP, thereby activating hepatic stellate cells, which accelerates the process of liver fibrosis. However, GCA did not directly activate hepatic stellate cells. This effect is relevant in the context of cholestatic disease, where glycocholic acid accumulates abnormally, rather than at physiological concentrations.
7.3 TPN and Pre-Existing Liver Disease
Serum glycocholic acid increased in patients with liver disease treated with a vitamin preparation containing glycocholic acid (Cernevit) in the context of total parenteral nutrition, whereas total bile acids did not significantly change. Other liver function tests remained stable during treatment. This finding indicates that patients with pre-existing hepatobiliary disease may accumulate elevated serum glycocholic acid when receiving parenteral vitamin formulations containing this compound, and their serum bile acid profiles warrant closer monitoring.
7.4 Association with Fetal Risk in Pregnancy
Clinical studies have confirmed that the risk of fetal adverse complications is closely related to maternal glycocholic acid levels, with the incidence of complications increasing significantly with increasing maternal glycocholic acid levels. Although ICP is rarely harmful to the mother, premature delivery, amniotic fluid contamination, fetal distress, and even fetal death are severe and common complications. These risks pertain to pathologically elevated endogenous levels, not to exogenous supplementation.
7.5 Association with Colorectal Cancer Risk
The plasma levels of seven conjugated bile acid metabolites, including glycocholic acid, were positively correlated with risk of colon cancer. This association, established in prospective epidemiological research, is observational. There is adequate evidence to support the role of microbiota in the metabolism of bile acids and how this relates to colorectal cancer, though further work is necessary to identify specific bacteria involved and their underlying mechanistic pathways.
7.6 Drug Delivery Interactions: Multidrug Resistance Proteins
Glycocholic acid at 250 μM decreases expression of the genes encoding multidrug resistance protein 1 (MDR1), MDR-associated protein 1 (MRP1), and MRP2, when used alone or in combination with epirubicin in Caco-2 cells. This effect on drug efflux pumps has implications for the co-absorption of drugs in pharmaceutical formulations that incorporate glycocholic acid as an excipient, suggesting that it could potentially alter the pharmacokinetics of co-administered drugs that are substrates of these transporters. This interaction has been characterized in vitro and has not yet been fully evaluated in clinical pharmacokinetic studies.
7.7 Overall Evidence Strength Summary
Current research on glycocholic acid is insufficient, with synthesis techniques requiring improvement, limited application of detection technologies, and a need for in-depth exploration of its pharmacological mechanisms. The evidence base for glycocholic acid spans several tiers:
- Well-established (physiological role): Fat and vitamin absorption, bile acid pool composition, enterohepatic circulation.
- Clinically validated (diagnostic biomarker): Serum levels as an indicator of hepatobiliary disease severity, ICP diagnosis and prognosis.
- Phase III clinical trial (therapeutic): Treatment of congenital bile acid synthesis disorders due to BAAT deficiency.
- Observational / prospective epidemiology: Association between elevated plasma glycocholic acid and colorectal cancer risk.
- Preclinical / in vitro only: Anti-inflammatory, antioxidant, and antibacterial properties; liver fibrosis mechanisms; drug efflux transporter modulation.
References
Volver